Posted: 05/22/2025 03:41 am
Recent press releases highlight Biofrontera's operational milestones, showcasing its momentum and commitment to expanding its therapeutic capabilities. The company reported the completion of the 1-year follow-up visit for the last patient involved in the Phase 3 study of Ameluz®-PDT for SBCC by December 2024. This marks a critical milestone, promising advancements in treatment methods available for skin cancer. Another highlight is the installation of the 100th commercial RhodoLED® XL lamp in the U.S., showcasing Biofrontera’s expanding market presence and technological proliferation in dermatological care.2
In a series of recent developments, Biofrontera has also achieved new patent protection for Ameluz® until 2043, alongside completing patient enrollment in a Phase 2b study for the treatment of moderate to severe acne vulgaris, utilizing their novel topical gel. These achievements align with Biofrontera’s strategic emphasis on broadening its therapeutic portfolio and securing long-term competitive advantages.3
Biofrontera's recent financial performance further highlights the company’s trajectory. Although its share price saw a slight decline recently, trading at $0.6461 with a market capitalization of approximately $6.1 million, these metrics must be considered within the context of ongoing research developments, product placements, and new patent applications vital for sustaining growth and value creation over time.4
As Biofrontera navigates through its various projects, investors and industry watchers continue to monitor its progress closely, especially in anticipation of upcoming earnings announcements. The company hosted its Q1 2025 earnings call, providing stakeholders with insights into financial results and future expectations, amidst its dynamic project pipeline and evolving market dynamics.5
1. [SEC Compensation Data](https://www.sec.gov/Archives/edgar/data/1858685/000164117225007772/0001641172-25-007772-index.htm)
2. [GlobeNewswire Press Releases](https://www.globenewswire.com)
3. [GlobeNewswire News](https://www.globenewswire.com/news-release/2025/05/15/3082497/0/en/Biofrontera-Inc-Announces-New-Patent-Protection-on-Ameluz-until-2043-and-the-Completion-of-Patient-Enrollment-in-Phase-2b-Study-of-Ameluz-aminolevulinic-acid-HCI-Topical-Gel-10-for.html)
4. [NASDAQ Price and Company Info](https://seekingalpha.com/article/4787718-biofrontera-inc-bfri-q1-2025-earnings-call-transcript)
5. [AccessNewsWire](https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/biofrontera-inc.-to-report-first-quarter-fy-2025-financial-results-on-1024168)
